| Chemical Properties | Back Directory | [Boiling point ]
490.895±45.00 °C(Press: 760.00 Torr)(predicted) | [density ]
1.469±0.06 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | [form ]
Solid | [pka]
12.130±0.70(predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
WNTinib (APS-8-100-2) is a multi-kinase inhibitor that selectively antagonizes β-catenin (CTNNB1) mutated hepatocellular carcinoma (HCC). WNTinib downregulates oncogenicWntsignaling by inhibiting KIT/MAPK and downstream EZH2 activation[1]. | [in vivo]
WNTinib (20 mg/kg; p.o.; 0-24 h) has a half-life of 9.38 hour, plasma concentration of 7 μM 24?h after oral dosing and detectable quantities of drug in blood plasma up to 72?h post-dosing[1]. | Animal Model: | mice[1] | | Dosage: | 20mg/kg | | Administration: | Tail vein injection; 5 days | | Result: | inhibited tumors |
| [References]
[1] Rialdi A, et al. WNTinib is a multi-kinase inhibitor with specificity against β-catenin mutant hepatocellular carcinoma. Nat Cancer. 2023 Aug;4(8):1157-1175. DOI:10.1038/s43018-023-00609-9 |
|
|